SLN Falls 8.1% After Pricing $175M ADS Stock Offering

Silence Therapeutics (SLN) fell 8.1% on Aug 11, 2026 after the company priced a large U.S. public offering of its ADSs.

What Silence Therapeutics announced

Silence Therapeutics said it priced its previously announced underwritten public offering of 12,962,963 American Depositary Shares (ADSs) in the U.S. at $13.50 per ADS. Each ADS represents three ordinary shares of the company.

The company also granted underwriters a 30-day option to buy up to an additional 1,944,444 ADSs at the public offering price (less underwriting discounts and commissions). Silence said gross proceeds are expected to be approximately $175 million before fees and expenses, excluding any exercise of the underwriters’ option.

The offering is expected to close on or about August 13, 2026, subject to customary closing conditions. Jefferies, Morgan Stanley, Cantor, and William Blair are acting as joint book-running managers.

What it means for Silence Therapeutics

This is a straightforward “raise cash by selling stock” move — and for a clinical-stage biotech, that cash can matter. The expected ~$175 million in gross proceeds could give Silence more flexibility to fund development of its siRNA therapies, support operations, and keep programs moving without relying solely on partnerships or other financing.

At the same time, issuing a large block of ADSs can increase the share count, which can pressure the stock in the near term as the market digests dilution and the new supply of shares. Pricing the deal at $13.50 per ADS also sets a reference point that traders often anchor to immediately after the announcement.

How the stock reacted

SLN sold off quickly and stayed lower through the close.

Window	Move
5 min	-2.2%
10 min	-5.0%
30 min	-6.1%
1 hour	-5.9%
end of day	-8.1%

On a market-relative basis, SLN was down 7.5% versus SPY the same day.